Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.
| Image |  |
|---|---|
| Description | scientific article published on 21 December 2016 |
| Author/s |
author: Karola Rittner Xavier Preville |
| Publication date | December 21, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |